as it says .....but leaving the beer for 2/3 weeks seems to make it subside...feels like you swallowed a cactus and its working its way down both sides from
ribsRib cage pain to belt line. i get it under both
ribsRib cage pain going accross. they did find h/pylori but not convinced its gone hence trying MASTIC GUM.....my doc recons im just a worryer
Are you having difficulty swallowing at this time? Female or male and what is your age, your background hx etc. How much beer do you drink daily, weekly or monthly? How was H-pyloric dx by blood test or endoscopy?
Your ribs start at you top of your torso and cover the lungs then all your other abdomen organs lie up under them. So you hurt as soon as you swallow and straight down in both sides of ribs? I am trying to get some data here.
Gastritis and esophagitis can and maybe the cause of your s/s I know this, however I would probably see a GI doctor for a work up if you have not already done this for comfirmation. H-pyloric can cause peptic ulcers did you know this? It is also erradicated by antibiotic therapy which I assume you are on sometimes antibiotics can cause stomach discomfort as well, but I recommend you talking to your your doctor or going to see a GI doctor and having a complete workup if you have not already!!!!!!!!
RN, C CLTC Telemetry certified
Did this cactus feeling start after antibiotic therapy? If so it could be the therapy and not to worry it will resolves itself once therapy is done.
I know antibiotics sometime while helping us get better on one hand can makes us feel lousy on the other. Erthromycin is one antibiotic that if you do not drink milk or eat with pretty soon after therapy you will feel as if you have a knife in you stomach.
Have you told you doctor about this feeling?
Good luck.
No they are not the same Aciphex is a PPI or Proton Pump Inhibitor, like Prevacid, Prilosec and Nexium. I do not know if I am getting better or this medicine just works better for me since I've tried all the others. It is for my erosive esophagus.
<BL><H1><b>Aciphex</h1></b></BL>
The active ingredient in ACIPHEX TM Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole sodium salt. It has an empirical formula of C18H20N3NaO3S and a molecular weight of 381.43. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions.
ACIPHEXTM is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium. Inactive ingredients are mannitol, hydroxypropyl cellulose, magnesium oxide, low-substituted hydroxypropyl cellulose, magnesium stearate, ethylcellulose, hydroxypropyl methylcellulose phthalate, diacetylated monoglycerides, talc, titanium dioxide, carnauba wax, and ferric oxide (yellow) as a coloring agent.
INDICATIONS
Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)
ACIPHEXTM is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered.
Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)
ACIPHEXTM is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD maintenance).
Healing of Duodenal Ulcers
ACIPHEXTM is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks.
Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome.
ACIPHEXTM is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.
DOSAGE AND ADMINISTRATION
Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)
The recommended adult oral dose is one ACIPHEXTM 20 mg delayed-release tablet to be taken once daily for four to eight weeks. (See INDICATIONS AND USAGE). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered.
Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD Maintenance)
The recommended adult oral dose is one ACIPHEXTM 20 mg delayed-release tablet to be taken once daily. (See INDICATIONS AND USAGE).
Healing of Duodenal Ulcers
The recommended adult oral dose is one ACIPHEXTM 20 mg delayed-release tablet to be taken once daily after the morning meal for a period up to four weeks. (See INDICATIONS AND USAGE). Most patients with duodenal ulcer heal within four weeks. A few patients may require additional therapy to achieve healing.
Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
The dosage of ACIPHEXTM in patients with pathologic hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered. Some patients with Zollinger-Ellison syndrome have been treated continuously with ACIPHEXTM for up to one year.
No dosage adjustment is necessary in elderly patients, in patients with renal disease or in patients with mild to moderate hepatic impairment. Administration of rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Due to the lack of clinical data on rabeprazole in patients with severe hepatic impairment, caution should be exercised in those patients.
ACIPHEXTM tablets should be swallowed whole. The tablets should not be chewed, crushed, or split.
HOW SUPPLIED
ACIPHEXTM 20 mg is supplied as delayed-release light yellow enteric-coated tablets.
The medication code number (E243) is imprinted on one side.
Bottles of 30 (NDC# 62856-243-30)
Unit Dose Blisters Package of 100 (10 x 10) (NDC# 62856-243-41)
Store at 25°C (77°F); excursions permitted to 15- 30°C (59- 86°F). Protect from moisture.
<b><h2><blink>Disease</Blink></H2></B>
1. a condition of abnormal function involving any structure, part, or system of an organism. 2. a specific illness or disorder marked by a specific set of signs and symptoms, it may be due to heredity, infection, diet, or environment. Compare condition, diathesis.
---------------------------------------------------------
Excerpted from Mosby's Medical Encyclopedia
Copyright (c) 1994-5, 1996, 1997 The Learning Company Inc. All Rights Reserved
<blink><b><h2>Condition</h2></b></blink>
1. a state of being. It refers to physical and mental health or well-being. 2. to train the body or mind. This is done through certain exercises and repeated exposure to a state or thing. See also classical conditioning.
---------------------------------------------------------
Excerpted from Mosby's Medical Encyclopedia
Copyright (c) 1994-5, 1996, 1997 The Learning Company Inc. All Rights Reserved